ADC Drug Map
CLICK ON THE HUMAN TO SEE WHICH ADCs ARE BEING DEVELOPED FOR THAT SPECIFIC ORGAN
Filter by Cancer
- Bladder cancer
- Myeloma
- Leukemia
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer
- Colorectal cancer
- Liver cancer
- Lung cancer
- Hodgkin's disease
- Lymphoma
- Mesenteric Lymphadenitis
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Rectal cancer
- Skin cancer
- Small Intestine cancer
- Spleen cancer
- Stomach cancer
- Ureteral cancer
- Urethral cancer
- Uterine cancer
- White blood cells
ADC
- AbGn-107 (Ab1-18Hr1)AbGenomics BV | Taiwan Branch
- AbGn-108AbGenomics International
- AbGn-110AbGenomics International
- ABT-414AbbVie (prior sponsor, Abbott)
- ADCT-402ADC Therapeutics SARL
- AGS-15EAgensys/Astellas
- AGS-16C3F (AGS 16C3F / AGS-16M8F)Agensys/Astellas
- AGS-16M8F (AGS 16C3F / AGS-16C3F)Agensys/Astellas
- AGS-22M6EAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- AGS62P1Agensys
- AMG 224Amgen
- AMG-595Amgen, Inc
- AMG172Amgen, Inc
- Anetumab Ravtansine (BAY 94-9343)Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc.
- Anti-ETBR (RG-7636)Genentech/Roche
- ARX788 HER2 ADCAmbrx
- ASG-15MEAgensys/Astellas
- ASG-22CEAstellas Pharma Inc/Agensys, Inc. Seattle Genetics, Inc.
- ASG-5MEAgensys/Astellas
- BAY79-4620 (3ee9 / BAY 794620 / BAY 79-4620)Bayer HealthCare AG, Berlin, Germany
- BIIB-015Biogen
- Bivatuzumab mertansineBoehringer Ingelheim (ImmunoGen)
- Brentuximab vedotin (SGN35 / Adcetris®)Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
- Cantuzumab mertansine (huC242-DM1)GlaxoSmithKline
- Cantuzumab Ravtansine (IMGN-242)ImmunoGen
- CD22-4APCatalent Pharma Solutions and Triphase Accelerator Corporation
- CDX-014Celldex Therapeutics
- Coltuximab Ravtansine (SAR 3419)Sanofi
- DEDN6526A (RG-7636 / RG7636)Genentech/Roche
- Denintuzumab mafodotin (SGN-CD19A / SGN-19A)Seattle Genetics (Bothell WA USA)
- DMOT4039A (DMOT-4039A / RG7600 / RG 7600)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- DSTA4637SGenentech
- EDO-772P/B776Mundipharma EDO GmbH
- EDO-B278Mundipharma EDO GmbH
- Enfortumab Vedotin (ASG-22ME / ASG-22MSE)Agensys (Santa Monica CA USA) / Seattle Genetics (Bothell WA USA) and Astellas Pharma (Tokyo, Japan).
- Epratuzumab–SN-38Immunomedics
- Gemtuzumab ozogamicinPfizer (Wyeth)
- Glembatumumab vedotin (CDX-011)Celldex Therapeutics, Inc. (Needham MA USA)
- GSK2857916 (J6M0-mcMMAF)GSK
- Hertuzumab
- HTI-1511Halozyme
- IGN523Igenica Biotherapeutics
- IMGN 289ImmungoGen
- IMGN 779ImmunoGen, Inc.
- IMGN-242ImmunoGen
- IMGN-388ImmunoGen
- IMGN-633 (AVE9633)ImmunoGen
- IMGN529 (K7153A) | Debio 1562 | Naratuximab EmtansineImmunoGen
- Indatuximab Ravtansine (BT-062)BioTest
- Indusatumab vedotin (MLN-0264)Takeda / Millennium Pharmaceuticals Inc. (Cambridge MA USA)
- Inotuzumab ozogamicin (CMC-544)Pfizer (Wyeth Pharmaceuticals)
- KTN0125Kolltan Pharmaceuticals
- KTN0182AKolltan Pharmaceuticals
- Labetuzumab-SN-38 (IMMU-130)(hMN-14-SN38)Immunomedics
- Lifastuzumab Vedotin (RG-7599 / DNIB0600A)Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)/Genentech
- LOP628 (LOP-628)Novartis Pharmaceuticals
- Lorvotuzumab mertansine (IMGN-901)ImmunoGen
- MDX-060 / iratumumabMedarex/Bristol-Myers Squibb
- MDX-1203Medarex/Bristol-Myers Squibb
- MEDI-547MedImmune
- MEDI4276 (MEDI 4276)Medimmune / AstraZeneca
- MI130004PharmaMar
- Milatuzumab-doxorubicin (hLL1-DOX)Immunomedics Inc. (Morris Plains NJ USA)
- Mirvetuximab Soravtansine (IMGN-853)ImmunoGen (Cambridge MA USA)
- MLN-2704Millennium/ Takeda
- MM-302Merrimack Pharmaceuticals, Inc.
- PF 06263507 (A1-mcMMAF / Anti-5T4 monoclonal antibody - Pfizer / PF-06263507Oxford BioMedica/Pfizer (Wyeth)
- PF-06647020Pfizer / Stemcentrx (AbbVie)
- PF-06647263Pfizer
- PF-06650808Pfizer
- Pinatuzumab vedotin (RG-7593 / DCDT2980S / DCDT-2989S)Genentech Inc. (South San Francisco, CA, USA) / Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- Polatuzumab vedotin (RG-7596 / DCDS4501A / DCDS-4501A)Genentech, Inc. (South San Francisco, CA, USA)/Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
- PSMA-ADCProgenics Pharmaceuticals, Inc. (Tarrytown NY USA)
- RC-48 (RC 48-ADC)Yantai Rongchang Biological Engineering (RemeGen)
- RG-7598 (DFRF 4539A / RG7598 / RG 7598)Genentech/Roche
- RG-7841 (Anti-Ly6E / DLYE5953A)Genentech/Roche (in collaboration with Seattle Genetic)
- RG7986Genentech/Roche
- RM-1929Aspyrian Therapeutics, Inc.
- Sacituzumab govitecan (IMMU-132 / hRS7-SN38)Immunomedics
- SAR 566658Sanofi
- SC16LD6.5Stem CentRx
- SGN CD70 A (superseding SGN-75)Seattle Genetics
- SGN-15 (BMS-182248, BR96-DOX)Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)
- SGN-CD123A
- SGN-CD19B
- SGN-LIV1A (Anti-LIV-1 ADC)Seattle Genetics, Inc., Bothell, Washington
- Sofituzumab vedotin (Anti-MUC16 ADC / RG7458 / DMUC5754A)Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
- SYD985Synthon
- Telisotuzumab Vedotin (ABBV 399)AbbVie
- Tisotumab Vedotin (HuMax®-TF-ADC)Genmab
- Trastuzumab-emtansine (T-DM1)Genentech/Roche
- Vadastuximab talirine (SGN-CD33A; EC-mAb)Seattle Genetics
- Vandortuzumab vedotin (Anti-STEAP1 ADC / RG7450 / DSTP3086S / MSTP2109A)Genentech Inc. (South San Francisco CA USA) / F. Hoffmann-La Roche Ltd (Roche)(Basel Switzerland)
- Vintafolide (EC145/MK 8109)Endocyte, Merck
- Vorsetuzumab mafodotin (SGN-75)Seattle genetics, Inc. (Bothell, WA, USA)
Recommended Blogs Posts
What Governments can do to Address Cancer
04 February, 2017
While much work remains to find a cure for cancer – the good news is we know that many forms of cancer are preventable. On World Cancer Day, a moment when the global community comes together to reflect on tho...
To Reimburse or not to Reimburse – That is the Question
08 November, 2016
Novel, innovative (bio)pharmaceutical drugs are an important part of our global healthcare system, offering advanced, radical new personalized and targeted therapy options to patients with life-threatening di...